- Supported exchanges /
- F /
- 5WK.F
ALIGOS THERAPEUT. DL-01 (5WK F) stock market data APIs
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
ALIGOS THERAPEUT. DL-01 Financial Data Overview
| 10.725 | |
| 10.725 | |
| - | |
| 10.725 | |
| 10.725 | |
| 7.15-25.5 | |
| 1 652 K | |
| 3 072 K | |
| 7 967 K | |
| 2.183 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
ALIGOS THERAPEUT. DL-01 Fundamental Data is available in our Financial Data APIs
- Net Revenue 7 967 K
- EBITDA -91 565 000
- Earnings Per Share -13.15
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get ALIGOS THERAPEUT. DL-01 Earnings via APIs
- Latest Release 2024-10-31
- EPS/Forecast NaN
Get ALIGOS THERAPEUT. DL-01 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
